Related Experiment Video
Updated: Aug 21, 2026

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP
Published on: April 9, 2013
Use of quinupristin/dalfopristin in a critical patient with a methicillin-resistant Staphilococcus aureus infection
E De Robertis1, D Viscidi, G Servillo
1Department of Anesthesia and Intensive Care, Federico II University, Naples, Italy. ederober@unina.it
Abstract:
The growing incidence of infections due to Gram-positive multiresistant germs has stimulated research into new drugs endowed with broader activity, that are useful in case of infections unresponsive to common antibiotics. The case of a 28-year-old man infected with a methicillin resistant Staphylococcus aureus non responder to therapy with glycopeptide antibiotics is reported. At admission the patient presented a septic condition and required mechanical ventilation. Antibiotic therapy was immediately started with teicoplanin+meropenem. Blood culture and bronchial aspirate evidenced a methicillin resistant Staphylococcus aureus with high sensibility to glycopeptide antibiotics. Although this therapy produced a slight improvement in clinical condition and the patient was extubated, fever and leucocytosis associated with a BAL positive to methicillin resistant Staphylococcus aureus, in vitro susceptible to glycopeptides, persisted. Considering the possibility of a non-responder condition of the patient to glycopeptide antibiotics, quinupristin/dalfopristin was added. The streptogramin produced a quick improvement in clinical condition with resolution of sepsis and culture sterilization. The patient improved progressively and was discharged. In conclusion, in our experience the association quinupristin/dalfopristin was effective in the resolution of a critical methicillin resistant Staphylococcus aureus infection non responder to classical treatment with glycopeptide antibiotics that showed a high sensibility in vitro.
Insights
A patient with a severe methicillin-resistant Staphylococcus aureus infection, unresponsive to glycopeptide antibiotics, was successfully treated with quinupristin/dalfopristin. This case highlights the efficacy of streptogramins for difficult-to-treat Gram-positive infections.
Area of Science:
- Infectious Diseases
- Pharmacology
- Critical Care Medicine
Background:
- Rising incidence of Gram-positive multidrug-resistant organisms necessitates novel therapeutic strategies.
- Methicillin-resistant Staphylococcus aureus (MRSA) infections pose a significant clinical challenge, often requiring alternative treatments.
Observation:
- A 28-year-old male presented with sepsis due to MRSA, initially treated with teicoplanin and meropenem.
- Despite initial improvement and extubation, the patient experienced persistent fever and leukocytosis with MRSA bacteremia.
- The MRSA isolate demonstrated in vitro susceptibility to glycopeptides, yet the patient did not respond to glycopeptide therapy.
Findings:
- Quinupristin/dalfopristin (a streptogramin) was added due to suspected glycopeptide non-response.
- This combination therapy led to rapid clinical improvement, sepsis resolution, and microbiological sterilization.
- The patient ultimately recovered and was discharged.
Implications:
- Quinupristin/dalfopristin can be an effective treatment option for critical MRSA infections unresponsive to standard therapies.
- This case underscores the importance of considering alternative antibiotics when patients do not respond to initial treatments, even with in vitro susceptibility.
- Further research into the role of streptogramins in managing multidrug-resistant Gram-positive infections is warranted.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Gene Regulation in Microbial Communities: Quorum Sensing
Mechanism of Antibiotic Resistance in MRSA
Staphylococcal Skin Infections
Acute Pyelonephritis II: Diagnostic Studies and Management
Hand hygiene
Hand washing...